

Real-World Effectiveness and Safety of Insulin Glargine 300 U/mL in Insulin-Naïve People with Type 2 Diabetes: the ATOS Study

Gagik R Galstyan^{1*}, Amir Tirosh², Hernando Vargas-Uricoechea³, Maria Aileen Mabunay⁴, Mathieu Coudert⁵, Mubarak Naqvi⁶, Valerie Pilorget⁵, Niaz Khan⁷

¹Endocrinology Research Centre of Health Care Ministry of Russian Federation, Dmitriya Ulyanova, Moscow, Russia

²Division of Endocrinology, Diabetes and Metabolism, Chaim Sheba Medical Center, Tel Hashomer, and Tel Aviv University, Tel Aviv, Israel

³Division of Endocrinology and Metabolism, Department of Internal Medicine, Universidad del Cauca, Popayan-Cauca, Colombia

⁴Sanofi, Singapore

⁵Sanofi, Paris, France

⁶Sanofi, Mumbai, India

⁷Imperial College London Diabetes Centre, Al Ain, United Arab Emirates

***Corresponding author:** Gagik R Galstyan

Email: galstyangagik964@gmail.com

Supplementary table 1: Insulin dose and body weight change from baseline

	Baseline	Month 3[†]	Month 6[†]	Month 12[†]
Basal insulin dose (U)	14.6 ± 6.5	19.6 ± 8.6	21.8 ± 9.5	23.3 ± 10.3
Absolute change from baseline (95% CI) ^a	–	4.9 (4.7–5.2)	7.1 (6.9–7.4)	8.6 (8.3–8.9)
Basal insulin dose (U/kg)	0.19 ± 0.09	0.25 ± 0.11	0.27 ± 0.11	0.29 ± 0.12
Absolute change from baseline (95% CI) ^a	–	0.06 (0.056–0.062)	0.08 (0.08–0.09)	0.10 (0.10–0.11)
Body weight (kg)	80.7 ± 16.3	81.4 ± 15.7	81.3 ± 15.5	81.4 ± 15.2
Change from baseline (95% CI) ^b		0.1 (–0.0–0.2)	–0.0 (–0.1 to 0.1)	–0.1 (–0.3 to –0.0)

Data shown are mean ± SD. Analyses were undertaken in the eligible population (*N* = 4422; those meeting the inclusion/exclusion criteria who started Gla-300 ± 31 days from the study start).


[†]The 3-month period was defined as from the first treatment administration to visit 2 (Month 3) or treatment discontinuation, whichever occurred first; the 6-month period was defined as from the first treatment administration to visit 3 (Month 6) or treatment discontinuation, whichever occurred first and the 12-month treatment period was defined as from the first treatment administration to visit 4 (Month 12) or treatment discontinuation, whichever occurred first.

^aDose change from baseline is presented as mean change from baseline (95% CI).

^bLS mean change was assessed using a mixed model for repeated measurements approach.

CI, confidence interval; LS, least squares; N, number; SD, standard deviation; U, units.

Supplementary figure 1: Participant disposition



*Other reason is defined as patients who met all inclusion/exclusion criteria but have not initiated Gla-300 within ± 31 days of start of study

HbA_{1c}, haemoglobin A_{1c}; Gla-300, insulin glargine 300 U/mL; T2DM, type 2 diabetes mellitus